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Male sex 683(76.7) 
Cause of cirrhosis  
HBValone 807(90.7) 
HBV+Alcohol 55(6.2) 
HBV+other hepatitis virus 17(1.9) 
HBV+schistosomiasis 11(1.2) 





Treatment with NUCs* 209(23.5) 
Cause of hospitalization at enrolment  
Ascites 506(56.9) 
Hepatic Encephalopathy 103(11.8) 
Bacterial infections 40(4.4) 
GI-bleeding 237(26.5) 
Other cause 4(0.4) 
Potential precipitating events(PE) of ACLF  
No PE’s 402(45.2) 
At least one PE 389(43.7) 
>1PE 99(11.1) 
Bacterial infection 94(10.6) 
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Gastrointestinal hemorrhage 67(7.5) 
Active alcoholism** 64(7.2) 
HBV reactivation 41(4.6) 
others 151(16.9) 
Previous decompensation  
No 400(44.9) 
Yes 490(55.1) 
Site of hospitalization at enrolment  
Intensive care unit 0(0.0) 
Ward 890(100.0) 
Laboratory data  
Hematocrit(%) 30±7 
Platelet count(x 109/L) 78±59 
Serum bilirubin(mg/dL) 11.8±14.9 
International normalized ratio 2.0±1.2 
Alanine aminotransferase(U/L) 156±394 
Aspartate aminotransferase(U/L) 139±293 
γ-Glutamyltransferase(U/L) 64±79 
Serum creatinine(mg/dL) 1.0±0.9 
Serum sodium(mmol/L) 134±9 
Leukocyte count(x109/L) 6.4±4.9 
MELD score at enrolment 20.2±9.4 
MELD na score at enrolment 22.6±9.3 
Liver failure 268(30.1) 
Kidney failure 89(10.0) 
Cerebral failure 46(5.2) 
Coagulation failure 232(26.1) 
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Respiration failure 11(1.2) 
Circulation failure 21(2.4) 
No organ ailure 510(57.3) 
1 organ failure 180(20.2) 
>1 organ failure 200(22.5) 
Renal dysfunction 46(5.3) 







Data are mean±Standard Deviation or n(%) 
*within 6months prior to enrolment 






















Supplementary Table S2. Characteristics and prognosis of patients with 
ACLF with and without prior history of AD. 
 
Characteristics Any prior 
AD 
(n=143) 
No prior AD 
(n=157) 
p-value 
Age(y) 46.9±10.4 46.1±12.0 0.518 
Male sex 102(71.3) 131(83.4) 0.012 
Ascites 110(76.9) 119(76.3) 0.896 
Cause of cirrhosis   0.243 
HBV alone 120(86.3) 143(91.1)  
HBV+Alcohol 13(9.4) 6(3.8)  
HBV+other hepatitis virus 4(2.9) 4(2.6)  
HBV+schistosomiasis 2(1.4) 4(2.6)  
HBV-DNA level(IU/ml)    
≤100 27(18.9) 33(21.0) 0.899 
>100-2x104 74(51.7) 83(52.9)  
>2x104-2x106 35(24.5) 33(21.0)  
>2x106 7(4.9) 8(5.1)  
Treatment with NUCs* 46(32.2) 49(31.2) 0.859 
Potential precipitating events of 
ACLF 
   
Bacterial infection 31(21.7) 28(18.0) 0.418 
Gastrointestinal haemorrhage 19(13.3) 4(2.6) <0.001 
Active alcoholism** 14(9.8) 16(10.2) 0.908 
HBV reactivation 19(13.3) 8(5.1) 0.013 
others 20(14) 20(14) 1.000 
No precipitating events 51(35.7) 84(53.5) 0.005 
At least one precipitating event 71(49.7) 61(38.9)  
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>1 precipitating events 21(14.7) 12(7.6)  
Organ failures    
Liver 102(72.3) 131(84.5) 0.011 
Kidney 44(31.0) 41(26.5) 0.388 
Cerebral 37(25.9) 34(21.7) 0.391 
Coagulation 91(64.1) 112(72.3) 0.130 
Circulation 35(24.5) 22(14.0) 0.021 
Lungs 21(14.7) 22(11.4) 0.868 
Renal dysfunction 21(15.1) 23(15.1) 0.996 
Cerebral dysfunction 28(19.6) 29(18.5) 0.807 
ACLF   0.197 
GradeI 25(18.1) 20(13.4)  
GradeII 55(38.5 77(49.0)  
GradeIII 31(22.5) 35(22.3)  
Laboratory data    
Leukocyte count(x109/L) 10.4±7.7 10.3±6.0 0.879 
Platelet count(x109/L) 81±68 88±58.8 0.335 
Serum bilirubin(mg/dL) 23.6±15.9 29.2±16.3 0.003 
International normalized ratio 3.1±1.9 3.3±2.2 0.322 
Alanine aminotransferase(U/L) 241±501 382±653 0.036 
Aspartate aminotransferase(U/L) 240±505 266±398 0.627 
γ-Glutamyltransferase(U/L) 54±54 83±122 0.007 
Serum creatinine(mg/dL) 1.6±1.7 1.5±1.3 0.007 
Mortality    
28 days 66(46.2) 66(42.0) 0.473 
90 days 74(51.8) 76(48.4) 0.563 
180 days 77(53.9) 76(48.4) 0.347 
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365 days 78(54.6) 77(49.0) 0.341 
 
 
Data are mean±Standard Deviation or n(%) 
*within 6 months prior to enrolment 





































Supplementary Table S3. Clinical characteristics and mortality according to the 








event but HBV 
DNA>500 
No Precipitating 
event and HBV 
DNA ≤500 
p-value 
 N=27 N=81 N=155 N=37  
Age(y) 41.5±8.6 48.3±10.7 45.7±11.5 49.1±12.3 0.018 
Male sex 21(77.8) 65(80.3) 117(75.5) 30(81.1) 0.805 
Previous decompensation     0.037 
No 8(29.6) 39(48.2) 87(56.1) 23(62.2)  
Yes 19(70.4) 42(51.9) 68(43.9) 14(37.8)  
Ascites 22(81.5) 61(75.3) 136(87.7) 29(78.4) 0.096 
Mean arterial pressure(mmHg) 95±15 85±15 85±13 88.7±14.9 0.002 
Organ failures      
Liver 25(92.6) 51(63.0) 121(78.1) 25(67.6) 0.007 
Kidney 6(22.2) 32(39.5) 41(26.5) 10(27.0) 0.147 
Cerebral 4(14.8) 5(6.2) 22(14.2) 12(32.4) 0.003 
Coagulation 19(70.4) 42(51.9) 90(58.1) 23(62.2) 0.360 
Circulation 2(7.4) 9(11.1) 7(4.5) 1(2.7) 0.183 
Lungs 1(3.7) 3(3.7) 4(2.6) 3(8.1) 0.460 
Renal dysfunction 3(11.5) 13(16.9) 24(15.8) 4(11.1) 0.813 
Cerebral dysfunction 9(33.3) 20(24.7) 24(15.5) 4(10.8) 0.043 
Laboratory data      
Hematocrit(%) 36±7 29±7 29±8 31±9 0.001 
Leucocytes 10.5±5.9 10.6±6.9 8.7±4.9 10.7±5.5 0.037 
Platelet count(×109/L) 86±42 91±74 86±60 86±60 0.937 
Serum bilirubin(mg/dL) 28±10 23±17 27±17 20±13 0.040 
International normalized ratio 3.3±1.3 2.6±1.1 2.9±1.4 3.7±3.1 0.008 
Alanine aminotransferase(U/L) 508±412 223±497 336±669 272±423 0.149 
Aspartate aminotransferase(U/L) 368±386 204±399 234±447 257±416 0.403 
γ-Glutamyltransferase(U/L) 86±84 83±122 64±81 51±47 0.234 
Serum creatinine(mg/dL) 1.6±2.8 1.5±1.2 1.3±1.3 1.6±1.4 0.561 
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Serum sodium(mmol/L) 130±7 131±8 129±7 131±7.7 0.105 
ACLF grades:     0.047 
ACLF-I 5(18.5) 17(21.0) 28(18.1) 5(13.5)  
ACLF-II 16(59.3) 31(38.3) 86(55.5) 14(37.8)  
ACLF-III 6(22.2) 33(40.7) 41(26.5) 18(48.7)  
Mortality      
28 days 12(44.4) 39(48.2) 56(36.1) 22(59.5) 0.047 
90 days 13(48.2) 46(56.8) 69(44.5) 23(62.2) 0.134 
180 days 13(48.2) 47(58.0) 71(45.8) 23(62.2) 0.158 
365 days 13(48.2) 47(58.0) 73(47.1) 23(62.2) 0.225 
 
 
Data are mean±Standard Deviation or n(%) 
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